Andrew Witty will lead Optum as CEO, Novartis' operations lead André Wyss steps down, Gilead bids farewell to longtime R&D lead Norbert Bischofberger.
Arbor Biotechnologies has emerged from the shadows with $15.6 million in funding and a CRISPR enzyme that targets RNA.
Two studies uncover links between genes and brain-cell functioning that could provide new targets for therapies aimed at neurodegenerative diseases.
Ionis Pharma is licensing two antisense drugs to Akcea Therapeutics, picking up a $150 million upfront fee.
The pair will focus on drugs against the MCL1 protein, which scientists believe is responsible for preventing cancer cell death.
Alexion hit key endpoints for its experimental phase 3 drug ALXN1210 in patients with a life-threatening ultrarare blood disorder.
In this week's EuroBiotech Report, Sanofi says no to Alnylam drug, Teva scraps Heptares deal, MorphoSys eyes FDA nod and more.
In our EuroBiotech roundup this week, Roche teams with BioMed X, U.K. makes cell therapy commitment and Amyrt licenses gene therapy platform.
Ideaya expects to get its first synthetic lethality and immuno-oncology assets into human testing in the first half of next year.
Median PFS is still ticking up in the trial of the CD19 antibody, adding weight to MorphoSys’ claims MOR208 can hold its own against CAR-T therapies.